Rocket Pharmaceuticals In... (RCKT)

NASDAQ: RCKT · Real-Time Price · USD

7.88

0.25 (3.28%)

At close: May 01, 2025, 3:57 PM

7.86

-0.19%

After-hours: May 01, 2025, 04:02 PM EDT

3.28% (1D)

Bid	7.78
Market Cap	839.71M
Revenue (ttm)	n/a
Net Income (ttm)	-258.75M
EPS (ttm)	-2.73
PE Ratio (ttm)	-2.88
Forward PE	-4.77
Analyst	Buy

Ask	7.98
Volume	2,486,184
Avg. Volume (20D)	2,522,235.9
Open	7.65
Previous Close	7.63
Day's Range	7.33 - 7.93
52-Week Range	4.55 - 26.98
Beta	1.00

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 18, 2015

Employees 299

Stock Exchange NASDAQ

Ticker Symbol RCKT

Website https://rocketpharma.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 496.83% from the latest price.

Stock Forecasts

Next Earnings Release

Rocket Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-2.38%

Rocket Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription

6 months ago

+8.27%

Rocket Pharmaceuticals shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating on the stock and announced a $50 price target.

News

3 weeks ago · seekingalpha.com

Rocket Pharma Out Of Orbit, But Ready For Relaunch

Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants....

4 weeks ago · businesswire.com

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...

2 months ago · zacks.com

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus

RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.

2 months ago · businesswire.com

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

2 months ago · seekingalpha.com

Rocket Pharma Is A Buy At These Prices With Promising Data

Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease ...